Abstract: Mitochondrial fatty acid -oxidation disorders are relatively common causes of acute metabolic crises and sudden death in infants. Most of these disorders can be treated effectively, provided, fasting is avoided and there is an early start of a high-carbohydrate low-fat diet therapy. Two disorders, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and complete mitochondrial trifunctional protein (MTP) deficiencies, have pathogenetically interesting and therapeutically challenging manifestations, which are atypical of -oxidation defects. In addition to the classical manifestations of disorders affecting -oxidation of long-chain fatty acids (hypoketotic hypoglycaemia, hepatopathy, cardiomyopathy and rhabdomyolysis), patients with LCHAD and MTP defects have pigmentary retinopathy, which causes visual handicap, progressive peripheral neuropathy and hypoparathyreosis. Furthermore, female carriers may have devastating pre-eclampsia-related complications and in particular acute fatty liver during pregnancy. Pathogenesis research of the important characteristic features of LCHAD and MTP deficiencies would not only improve opportunities for new therapeutic strategies but could increase our understanding of tissue metabolism affected by these disorders.
Mitochondrial fatty acid -oxidation coupled with the respiratory chain is the major source of energy for metabolically active human tissues, especially skeletal and cardiac muscle and the kidneys. This is emphasized even more during prolonged periods of fasting and exercise. Mitochondrial -oxidation is a complex process requiring transport of the activated acyl-coenzyme A (CoA) moiety into the mitochondria and sequential removal of two-carbon acetyl-CoA units. The -oxidation process requires fatty acids entering the mitochondria, across the selectively permeable mitochondrial membranes. Free fatty acids are activated to their respective CoA esters at the outer mitochondrial membrane. The rate-limiting step in the transport of long-chain fatty acids into the inner mitochondrial matrix is the one controlled by carnitine palmitoyltransferase1 (CPT1). Once inside the mitochondria, acyl-CoA undergoes a set of four reactions, each catalyzed by a different enzyme. The set of four reactions is repeated until the fatty acid is broken down into 2-carbon moieties of acetyl-CoA [1] . As the fatty acyl-CoA substrate becomes shorter, enzymes with different chain length specificities are required. The enzyme responsible for the first reaction in the cycle of the oxidation of long-chain fatty acids is the very long-chain acyl-CoA dehydrogenase (VLCAD). This reaction involves dehydrogenation of the C2-C3 bond and the production of 2,3-enoylCoA. The second step in the cycle is the hydration of the 2,3-enoyl-CoA to generate L-3-hydroxyacyl-CoA. The enzyme involved in this reaction is long-chain 2,3-enoyl-CoA (LHYD). The third step of the cycle is catalyzed by longchain 3-hyroxyacyl CoA dehydrogenase (LCHAD), which oxidizes 3-hydroxy position to yield a 3-ketoacyl-CoA. The last reaction involves thiolytic cleavage of the 3-ketoacylCoA to acetyl-CoA and acyl-CoA shortened by two carbons. This step is catalyzed by long-chain 3-ketoacyl-CoA thiolase (LKAT). Further, the first step of -oxidation of the long chain fatty acids creates FADH2 and the third step NADH, which are then reduced in the respiratory chain for generation of ATP. For a more detailed description of the enzymatic reactions involved, see Rakheja et al. 2002 [2] .
The acetyl-CoA generated via -oxidation can be directly utilized as an energy substrate within the citric acid cycle (skeletal muscle) or channeled into ketogenesis or gluconeogenesis in the liver. The liver can degrade acetyl-CoA to ketone bodies, acetoacetate and -hydroxybutyrate for tissues not capable of -oxidation. Although the brain and eye rely mostly on glucose oxidation, during prolonged fasting, the brain is also capable of utilizing ketone bodies for generation of ATP [3] .
Three of the four enzymes involved in the mitochondrial -oxidation of long-chain fatty acids -LHYD, LCHAD and LKAT -all reside in a single protein called the mitochondrial trifunctional protein (MTP) [4, 5] . Human MTP is a multienzyme complex bound to the inner mitochondrial membrane. It is a hetero-octamer composed of foursubunits and four -subunits. The amino terminal domain of the -subunit contains the LHYD activity, whilst the LCHAD activity resides in the carboxyterminal domain of this subunit. The -subunit harbors the LKAT activity [6] . The -and subunits of MTP are encoded by separate genes, HADHA (MIM# 600890) and HADHB (MIM# 143450), respectively, which are located contiguously (back to back) on chromosome 2p23 [6] [7] [8] .
MTP DEFICIENCIES
Defects in mitochondrial fatty acid -oxidation are an important group of inherited metabolic disorders usually manifesting during infancy or childhood as life-threatening metabolic crises with hepatopathy and hypoketotic hypoglyaemia. In defects of long-chain fatty acid oxidation, these crises also feature myopathy and cardiomyopathy [9, 10] . As other -oxidation defects, deficiencies of mitochondrial trifunctional protein are also autosomally recessively inherited. Mutations in either -or -subunits of the MTP may result in MTP deficiency with reduced activities of all three enzymes [11] . Two main biochemical phenotypes of MTP deficiency can be recognized. In the complete form, all three enzymes are deficient and no immunoreactive protein can be detected. Multiple sporadic mutations in either the - [12] [13] [14] [15] [16] [17] [18] [19] [20] or -subunit [19, [21] [22] [23] have been recognized. In the other phenotype, the LCHAD enzyme is primarily affected, with only partial deficiency of the thiolase activity and a normal amount of immunoreactive protein. This condition first described by Wanders et al. in 1989 is often classified as LCHAD deficiency [24] . A common mutation has been identified in the gene coding for the -subunit of the MTP, in the domain responsible for LCHAD activity. In the majority of LCHAD-deficient patients, at least one of the alleles carries the G1528C mutation substituting glutamate at the amino acid position 474 by a glutamine residue (E474Q) [9, 13, [25] [26] [27] [28] [29] . Few cases with isolated LKAT deficiency have been reported [30] [31] [32] .
CLINICAL PRESENTATION OF COMPLETE MTP DEFICIENCY
Since the first description of the complete MTP deficiency in 1992 [33, 34] , a growing number of patients have been reported. The clinical phenotype of the disease shows great variability. Three different phenotypic groups have been described: (1) a lethal form with predominating cardiomyopathy; (2) an infancy-onset form with mainly hepatic presentation; and (3) a milder, later-onset form with neuromyopathic presentation [22, 30] . The lethal phenotype is characterized by severe dilated cardiomyopathy, lactic acidosis, and a Reye-syndrome like presentation with hypoketotic hypoglycemia and hepatic encephalopathy often progressing to coma and neonatal death. In almost all reported cases with complete MTP deficiency of the earlyonset phenotype, patients have died in the first weeks of life despite immediate therapeutic interventions. The hepatic phenotype however, is less severe. It usually presents in the first months of life with episodes of hypoketotic hypoglycemia and lethargy often triggered either by minor infections or fasting.
Given the severe and often fatal phenotypes of MTP deficiency in infancy, it appears then surprising that the same disorder may manifest later on in childhood and even in adolescence or adulthood. Only about one half of the patients demonstrate the fatal form of the disease [15, 30] . A number of cases have recently been published with a neuromuscular phenotype of MTP deficiency [14, 22, [35] [36] [37] . The mildest form of MTP deficiency is characterized by progressive peripheral neuropathy and episodic, often exercise-induced myoglobinuria, severe muscle weakness, myalgias and rhabdomyolysis. These muscular symptoms are usually provoked by prolonged exercise. During acute episodes, serum creatine kinase (CK) concentration may be highly elevated, while between the episodes, it is often normal or only slightly elevated [14, 35, 37] .
The peripheral neuropathy in total MTP deficiency typically involves the lower limbs [22] . A few patients also exhibited a milder involvement of the upper extremities with symmetric weakness of wrist and finger extensor muscles including a couple of patients who had facial weakness. In a study by Spiekerkoeter et al. on 11 patients with the neuromuscular form of total MTP deficiency, the episodes of rhabdomyolysis were accompanied by respiratory failure in 45% of the patients, suggesting severe weakness of the diaphragm and other respiratory muscles [36] . Similar findings were also observed in MTP deficient mice [38] . In most patients, the onset of the neuropathic features preceded rhabdomyolysis. In follow-up studies, evidence of the progression of neuropathy was observed in about 60% of patients despite dietary treatment and avoidance of fasting. Findings of nerve conduction studies suggest predominantly sensory axonal neuropathy. Sural nerve biopsies demonstrated axonal degeneration and loss of normal myelin [36] .
Diseases of patients with different phenotypes result from heterogeneous -or -subunit mutations with no prevalent mutations having been detected [30, 39] . Interestingly, in a few patients with MTP deficiency, peripheral neuropathy presented with no signs of liver involvement, suggesting tissue specificity [14] . Despite wide variability in the clinical presentation of the patients with MTP deficiency, only few reports of possible genotype-phenotype correlation have been published. Ibdah et al. proposed a genotype-phenotype correlation by reporting two patients with neuromuscular phenotype both carrying missense mutations in exon 9 of the -subunit. These mutations allowed stable MTP expression but were predicted to result in defective subunit interaction and octamer formation, thus leading to complete MTP deficiency [14, 40] . A recent report by Das et al. described a case of isolated LKAT deficiency resulting from compound heterozygosity for missense mutations in the HADHB-gene [31] . The patient presented with lethal cardiac phenotype. (600890)) is associated with missense mutations in the catalytic site of the LCHAD domain. A common mutation, G1528C, has been identified, and in the majority of LCHAD-deficient patients, at least one allele carries this point mutation. All the mutations result in intact mutant protein with significantly reduced LCHAD activity, while the activities of LHYD and LKAT enzymes usually remain at least 60% of the normal. Clinical presentation of isolated LCHAD deficiency is more uniform than that of the complete MTP deficiency. Patients usually exhibit moderate or severe multiorgan involvement either neonatally or during the first two years of life. The most prominent finding at presentation is liver involvement with hypoketotic hypoglycaemia. Additional features include cardiomyopathy, severe liver disease with cholestasis, and hypotonia during the first two years of life [28, 41] . Liver histology has shown steatosis and in advanced cases, fibrosis or cirrhosis [42, 43] . LCHAD deficiency generally leads to high morbidity and mortality, but the disorder can also be consistent with long-term survival in patients diagnosed and treated from an early age [28, 39, 41] .
CLINICAL PRESENTATION OF ISOLATED LCHAD DEFICIENCY

Isolated LCHAD deficiency (McKusick
Peripheral neuropathy is usually a long-term complication in LCHAD deficiency and only occasional patients have been reported with symptomatic neuropathy [28, 41] . Since only few patients with LCHAD deficiency and longterm survival have been reported, it is probable that the neuropathy is more frequent and an important feature also in this disorder. As in patients with complete MTP deficiency, the neuropathy in LCHAD deficiency mainly affects the lower extremities and is of a sensory axonal type. Hypotonia and rhabdomyolysis are also features of LCHAD deficiency presenting either as a part of metabolic decompensation in infancy or as isolated manifestation later in childhood or adulthood. Rhabdomyolysis is often provoked by cold, prolonged exercise or infection [28, 41] .
RETINOPATHY AND HYPOPARATHYROIDISM IN LCHAD AND MTP DEFICIENCIES
Progressive pigmentary retinopathy is the major longterm complication in patients with LCHAD and MTP deficiencies. Of these two forms of MTP deficiency, pigmentary retinopathy seems to be typical for isolated LCHAD deficiency [29] . The lower occurrence of progressive ocular complications in patients with complete MTP deficiency might be explained by the fact that the neonatal presentation is very severe with high mortality and the retinopathy escapes detection. In the milder adult forms of complete MTP deficiency, fundus changes may be too mild to become symptomatic and therefore, recognized. Several cases with pigmentary retinopathy in patients with LCHAD deficiency have been reported [29, [44] [45] [46] [47] [48] . These cases have shown acquired and progressive disturbances of retinal pigment epithelium (RPE), usually consisting of a hyperpigmented central macular spot and more widespread pigment clumps in the central and peripheral fundus. These fundus changes have been accompanied by compromise of central and peripheral vision and dark adaptation. Electroretinography in individual patients has revealed abnormalities of both rod and cone system.
In our retrospective review of the ophthalmological records of 15 LCHAD-deficient children that died during the first two years of life, seven had pale fundi or normal ophthalmoscopic findings, whereas all the others had a coarsely granular RPE either with or without pigment aggregations and clumping in the macula [29] . In two longterm survivors aged 16 and 31 years with delayed onset of dietary therapy, the retinopathy progressed to the circumscribed atrophy of the fundus, sparing only the far periphery. They had progressive axial myopia, at least partly related to bulging of the central globe, staphyloma and paracentral scotoma leading to poor central vision. All the four surviving patients aged 5 to 31 years had visually insignificant, flakelike supranuclear opacities in the lens. Based on these findings, in pigmentary retinopathy of LCHAD deficiency, four stages of ocular manifestations can be characterized. In stage one, the fundus is normal. Stage two usually develops in infancy and is defined by pigment dispersion and degeneration of RPE. This is followed by circumscribed chorioretinal atrophy, occlusion of choroidal vessels and deterioration of central vision in stage three. Finally, in stage four, posterior staphylomas and central scotomas may develop [29] . Ophthalmopathological findings of a patient with LCHAD deficiency have suggested that the choroid and RPE would be primarily affected in the retinopathy. All the patients in our series were homozygous for the G1528C mutation of LCHAD deficiency.
Interestingly, hypoparathyroidism evidenced by hypocalcemia, hyperphosphatemia and a low level of parathyroid hormone was described in one patient with LCHAD deficiency [28] and in two patients with complete MTP deficiency [49, 50] . Insomuch as none in a series of 51 patients with LCHAD deficiency had hypoparathyroidism [41] , this association must be rare. The cause of the hypoparathyroidism and its link to the metabolic defect remain unclear. It has been suggested that the defect in the parathyroid function could be due to energy deprivation or accumulation of toxic long-chain fatty acid oxidation metabolites [50] . Considering hypoparathyreosis may be the first sign of LCHAD deficiency, awareness of this association is important.
PATHOGENESIS OF LCHAD AND MTP DEFI-CIENCIES
The pathogenesis of the characteristic features of LCH AD and MTP deficiencies remains unknown. Generally, the most tempting hypothesis for the pathogenesis of pigmentary retinopathy and peripheral neuropathy is the potential toxicity of 3-hydroxylated intermediates accumulating in the disorders, which could explain the pathogenesis of both of these clinical manifestations. The hypothesis was given some support by the finding of a positive correlation between 3-hydroxylated intermediates and the severity of the retinopathy in 14 patients with various defects of MTP deficiency [51] . It has also been proposed that the theoretical mechanism for this toxicity could be the potential interference of these substances with the biosynthesis of DHA, which has a major role in the function of neural and retinal membranes. This assumption is partly supported by the observation that at least in some patients, the DHA supplementation treatment resulted in a marked clinical and electrophysiological recovery [52] . A similar hypothesis has been applied for the retinopathy in peroxisomal disorders [48, 53] . Yet another theoretical explanation for the retinopathy and neuropathy could be the secondary respiratory chain dysfunction, detected both in vitro [54] and in patients with LCHAD deficiency [55] .
Since RPE and choroid are affected early on in the retinopathy of LCHAD deficiency, we studied metabolism of the RPE at the early stages [56] . Somewhat surprisingly, we found that in vitro cultured porcine RPE cells possessed the machinery for mitochondrial fatty acid -oxidation and carnitine uptake; normal chain shortening of palmitic acid and production of acylcarnitine was detected in these cells. Immunoblotting showed MTP in the cultured RPE-cells, and in immunohistochemistry, MTP expression was detected in several layers of the human retina including the RPE. Further immunohistochemical studies showed selective labelling of several cell types of the human eye but not the brain withoxidation antibodies. This demonstrated these enzymes are not ubiquitously expressed in tissues protected by a bloodtissue barrier [57] . Although the findings contradict most of the hypotheses on the pathogenesis of MTP deficiencies, we cannot rule out the possibility that either MTP or the whole fatty acid -oxidation pathway would have a role in the metabolism of ocular tissues.
WHEN TO CONSIDER THESE DISORDERS?
Due to the unusual features for -oxidation defects, LCHAD and MTP deficiencies can manifest with a multitude of clinical presentations. While hypoglycemia and acute metabolic crises usually occur neonatally or during infancy, the neuromuscular manifestations may present from early childhood until middle age. The mild phenotype of MTP deficiency may resemble that of the hereditary motorsensory neuropathy (HMSN) or spinal muscular atrophy (SMA). The combination of myopathy and peripheral neuropathy should arouse suspicion for MTP deficiencies. Moreover, these patients may present with hepatomegaly, cholestatic liver disease, cardiomyopathy, or hypoparathyreosis.
To improve the otherwise mainly poor prognosis of these disorders a rapid diagnosis is essential. Although most of the published reports on LCHAD deficiency suggest that the majority of LCHAD deficient patients present with acute metabolic crises, several patients have nevertheless exhibited a combination of non-specific symptoms probably related to LCHAD disease before the first hypoglycemic episode. In a large series of 50 patients suffering from isolated LCHAD deficiency, more than 20% of the patients presented with a variety of chronic problems, such as failure to thrive, growth retardation, muscular hypotonia and feeding difficulties [41] . Further, a retrospective evaluation of the clinical history of the patients revealed that 86% of them initially had chronic rather than acute problems. In the same study, it was shown that the generally high mortality rate (38% of the patients died either before or within 3 months after diagnosis) was significantly reduced, if the diagnosis was made before acute decompensation and irreversible organic failure had occurred.
DIAGNOSIS OF LCHAD AND MTP DEFICIENCIES
Whereas most abnormalities can be detected with a laboratory test only during acute symptoms or prolonged fasting, and since provoked fasting may be hazardous for the patients, it is important to take adequate specimens during acute symptoms. During acute hypoglycemia, hypoketotic response and high concentration of free fatty acids (FFA) can be detected. Furthermore, a search for organ involvement (ultrasound imaging and serum creatine kinase and amino transferase concentrations in laboratory tests) is warranted. The findings often made during acute symptoms are metabolic acidosis, lactic acidemia, and mild hyperammonemia. When accumulating -oxidation intermediates are bound to free carnitine, it causes their loss in the urine and as a result, secondary carnitine deficiency. Another biochemical marker suggesting either forms of MTP deficiency is 3-hydroxy dicarboxylic aciduria detected by gaschromatography. More specific changes can be found by undertaking plasma acylcarnitine analysis using tandem mass spectrometry, even during the stable phase of the disease; this test is the most useful for screening -oxidation defects. In patients with isolated neuromuscular manifestations, exercise or fasting studies may be needed to reveal metabolic abnormalities. The typical profile for LCHAD and MTP deficiencies consists of 3-hydroxy C16:0-, C16:1-, C18:0-, and C18:1-acylcarnitines [17, 58] ; diagnosis can be confirmed either by enzyme measurement in cultured cells (fibroblasts or lymphocytes) or by molecular genetic analyses [9] .
NEONATAL SCREENING AND PRENATAL DIA-GNOSIS FOR MTP DEFICIENCIES
Opportunity for dietary treatment, which may essentially alter the otherwise poor prognosis of most patients with LCHAD and MTP deficiencies has encouraged investigators to develop neonatal screening programs for these diseases. In several countries, LCHAD and MTP deficiencies have been included in the routine screening program by tandem mass spectrometry [32, 59] . As the screen does not discriminate between isolated LCHAD deficiency and other defects of MTP, all forms of MTP deficiencies are potentially detected. In Germany, 1.2 million samples were screened altogether and 11 MTP deficiencies were flagged from the samples analyzed. The metabolic defect was subsequently confirmed either by enzyme analysis in cultured fibroblasts or by mutation analyses. Of these, seven children had isolated LCHAD deficiency, two with complete MTP deficiency, and two with isolated deficiency of LKAT. No false negative results came to the attention of the authors [32] .
The presence of one common mutation in LCHAD deficiency responsible for the majority of disease cases offers possibilities for genetic pre-and postnatal screening for the disease in countries, which have a high proportion of this common mutation. Mutation analyses have shown that the common mutation G1528C is found in 60-100% of affected alleles in patients with LCHAD deficiency originating from different populations. In Finland, all the patients diagnosed with LCHAD deficiency, have so far been homozygous for the common mutation; the carrier frequency was found to be 1:240 [28, 60] . Similar frequencies (1:224 and 1:200) have been reported in Poland and Denmark, respectively (Piekutowska-Abramczuk et al. 2005 (abstract)). Prenatal diagnosis of LCHAD and MTP defects is also available, and is of particular value for those pregnant women with a high-risk for pregnancy complications. Both biochemical and molecular genetic analyses can be used [20, 59] .
THERAPY
The current management of LCHAD and MTP-deficient patients mainly includes avoidance of fasting and restriction of long-chain dietary fat (LCFA). During the low-fat diet, the needs for essential fatty acids and fat-soluble vitamins must be covered. It is also common practice to provide about 30% of the calories as even-chain medium-chain triglycerides (MCT) as this bypasses the metabolic block [61] [62] [63] . The frequency of feeding, dietary fat restriction, and the type and amount of other supplements varies from one centre to another. In a few centres, the treatment has been intensified by a stricter feeding regimen including gastrostomy tube with continuous overnight feeding [32] .
Gillingham et al. analysed the dietary intake and metabolic control in 10 children with either LCHAD or complete MTP deficiency. The patients consumed an average of 11% of caloric intake as dietary LCFA, 11% as MCT, 12% of protein and 66% as carbohydrate. They demonstrated, that as dietary intake of LCFA decreased and MCT intake increased, there was a corresponding decrease in plasma hydroxyacyl carnitines [62] . Similar results have been obtained by in vitro studies using cultured skin fibroblasts from LCHAD-deficient and normal individuals [63] and in smaller clinical studies [64] [65] [66] [67] . These studies also suggested MCT can be beneficial not only for bypassing the metabolic block, but also for actually inhibiting the accumulation of toxic long-chain intermediates. However, in a recent study by Jones et al., it was shown that in cell culture conditions medium-chain length fatty acids were elongated to 3-hydroxy-fatty acid intermediates two carbons longer than the precursor substrates suggesting a novel metabolic elongation pathway [68] . Further studies are needed for resolving the possible implications of this metabolic step for the therapeutic use of MCT in defects of fatty acid oxidation. Based on the results obtained from patients with VLCAD deficiency, it has been proposed that replacing dietary evenchain MCT by odd-chain MCT would be more beneficial also for treatment of LCHAD deficiency [61] . However, the usefulness of supplementation with odd-chain MCT instead of traditional MCT containing mainly octanoate and decanoate, in patients with LCHAD deficiency has not been established [62] . Docosahexanoic acid (DHA) is an essential polyunsaturated fatty acid highly concentrated in the phospholipids of the synaptosomal, mitochondrial, and microsomal membranes in the brain and the outer segments of the rod photoreceptors in the retina [69] . DHA deficiency has been documented in few children with LCHAD deficiency [64] . Because of its important role in retinal function, DHA deficiency has been proposed as one of the etiological factors in the development of retinopathy associated with LCHAD deficiency. Restriction of dietary LCFA intake to less than 10% of caloric intake is a risk factor for essential fatty acid deficiency [70] . The efficacy of adding moderate amounts of DHA (60-100mg/day) to the daily diet in the treatment of retinopathy associated with LCHAD deficiency was monitored in a recent study by Gillingham et al. [51] . Their results suggested that DHA supplementation could improve visual acuity, which was determined by visual evoked potentials. In a case report by Tein et al., a LCHAD-deficient patient suffering from severe neuropathy showed a marked response to treatment with cod liver oil, an important source of DHA [52] .
Few data are available on the use of L-carnitine supplementation in the treatment of -oxidation defects. The case of a 26 year-old patient with MTP deficiency and related recurrent myoglobinuria, muscle pain, and a marked increase in blood lactate values, was shown to benefit from a low-dose L-carnitine supplementation (300mg/day) while higher doses failed to prevent rhabdomyolysis with lactic acidosis during exercise [71] . In a series of 10 LCHADdeficient patients obtaining 10-153mg/kg L-carnitine per day, no correlation between carnitine supplementation and plasma hydroxyacylcarnitine or plasma organic acid levels was observed [62] . Supporting this, in another study conducted by den Boer et al. on 50 patients with LCHAD deficiency, no correlation was detected between carnitine supplementation and the frequency of metabolic decompensation [41] . These data suggest that dietary intake of carnitine is not essential for metabolic control in LCHAD deficiency.
The long-term outcome of patients treated with diet modifications remains unclear. Recent investigations have focused on the development of therapies that aim at correcting the metabolic defects in fatty acid oxidation. Angdisen et al. explored the potential use of protein transfection domains for the treatment of these diseases [40] . In the future gene and protein transfer technology might provide alternative therapeutic strategies for inherited metabolic diseases.
Further studies, are needed to gain a better understanding of the pathogenesis of all interesting features of LCHAD and MTP deficiencies including progressive pigmentary retinopathy and peripheral neuropathy. This is important because retinopathy and neuropathy cause severe morbidity. Lastly, further work is needed for finding the optimal dietary regimen for these disorders and their major complications.
